Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Losartan

Sana Mulla, Preeti Patel, Waqas J. Siddiqui  1
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Losartan

Sana Mulla et al.
Free Books & Documents

Excerpt

Losartan is an angiotensin receptor blocker (ARB) approved by the US Food and Drug Administration (FDA) for the treatment of several medical conditions, including hypertension and diabetic nephropathy. Losartan inhibits angiotensin II–induced vasopressin release, adrenal catecholamine release, rapid and slow pressor responses, thirst, cellular hypertrophy and hyperplasia, noradrenergic neurotransmission, and sympathetic tone increase.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Sana Mulla declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Waqas Siddiqui declares no relevant financial relationships with ineligible companies.

References

    1. Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA. Losartan: Comprehensive Profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:159-94. - PubMed
    1. Ruggenenti P. Dual renin-angiotensin system blockade for nephroprotection. Nephrol Ther. 2017 Apr;13 Suppl 1:S43-S45. - PubMed
    1. den Hartog AW, Franken R, van den Berg MP, Zwinderman AH, Timmermans J, Scholte AJ, de Waard V, Spijkerboer AM, Pals G, Mulder BJ, Groenink M. The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations. Neth Heart J. 2016 Nov;24(11):675-681. - PMC - PubMed
    1. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997 Mar 15;349(9054):747-52. - PubMed
    1. Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, Dasbach EJ, Carides GW, Dickstein K, Riegger G, Camm AJ, Martinez FA, Bradstreet DC, Ikeda LS, Santoro EP, ELITE II Investigators Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J. 2005 Jul;150(1):123-31. - PubMed

Publication types

LinkOut - more resources